Your gut bugs may hold the key to lung cancer therapy
NCT ID NCT04711330
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at whether bacteria in the gut and throat can predict how well stage III lung cancer patients respond to the immunotherapy drug durvalumab after chemoradiation. Researchers will collect stool, throat swabs, and breath samples from 126 participants to see if these microbes can forecast treatment success or side effects. The goal is to find a non-invasive way to personalize treatment decisions.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
durvalumab (immunotherapy)
What this could lead to
If successful, this could lead to a simple stool or throat swab test to predict which patients will benefit from durvalumab and who might experience side effects.
What could go wrong
This is an observational study, not a treatment trial. The microbiome analysis is exploratory, and results may not lead to a reliable test. The study is also relatively small (126 participants).
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IMMUNOTHERAPY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ingel Demedts
Roeselare, B8800, Belgium
-
Kristof Cuppens
Hasselt, Flanders, 3500, Belgium
-
Leiden University Medical center
Leiden, 2333ZA, Netherlands
-
Lynn Decoster
Turnhout, B2300, Belgium
-
Netherlands Cancer Institute
Amsterdam, 1066CX, Netherlands
-
Piet Verkouteren
Aalst, B-9300, Belgium